Shots:

• Regeneron advances its program to discover and develop a novel multi-Ab cocktail- administered as prophylaxis before exposure to the SARS-CoV-2 virus or as a treatment for already infected patients
• The company plans to initiate the clinical studies by early summer and has isolated mAb from its VelocImmune mice and from humans who have recovered from COVID-19 and would pick two of them to test as a cocktail treatment
• The program follows Regeneron's ongoing clinical program evaluating Kevzara (sarilumab- an IL-6 receptor antibody) in severe COVID-19 patients

Click here ­to­ read full press release/ article | Ref: Regeneron  | Image:  Regeneron